Polyrizon partners with Clearmind to develop intranasal MEAI formulation

Polyrizon Ltd. (NASDAQ: PLRZ) announced it has signed a development agreement with Clearmind Medicine Inc. (NASDAQ: CMND) to create an intranasal formulation of MEAI, a non-hallucinogenic neuroplastogen drug candidate for treating addiction and central nervous system conditions.

Under the agreement, Polyrizon will develop a proprietary intranasal formulation of MEAI (5-methoxy-2-aminoindane), Clearmind's drug candidate intended for addiction-related and other CNS conditions. The collaboration aims to advance the intranasal MEAI formulation to support Clearmind's future clinical development programs.

Polyrizon's intranasal technology platform is designed to enhance nasal residence time through gel-like mechanisms, provide consistent delivery of active compounds, and offer formulation flexibility tailored to the physicochemical profile of the active pharmaceutical ingredient.

The intranasal delivery route may offer advantages over oral administration for CNS-targeted treatments, including bypassing first-pass metabolism for more direct systemic access, potentially faster absorption, and lowering effective doses.

"We are proud to collaborate with Clearmind on the development of an intranasal formulation of MEAI," said Tomer Izraeli, Chief Executive Officer of Polyrizon. "Our proprietary intranasal technology is designed to enable more targeted, efficient delivery, and we believe it may offer meaningful value as Clearmind advances MEAI through its clinical pathway."

Polyrizon is a development-stage biotech company specializing in innovative medical device hydrogels delivered as nasal sprays. Clearmind is a clinical-stage biopharmaceutical company focused on psychedelic-derived therapeutics, with shares listed on Nasdaq under "CMND" and the Frankfurt Stock Exchange under "CWY0."

The information is based on a press release statement from the companies.

You May Also Be Interested In

• Kevin Knight retires from Knight-Swift Transportation
• Tucows shareholders elect board including new CEO David Woroch
• Commercial Vehicle Group (CVGI) files $25M mixed shelf